• PDF: Immediate delivery

MarketVIEW: Chlamydia trachomatis vaccines
Global market forecast

  • Publication Date:June 2012
  • Publisher:VacZine Analytics
  • Product Type: Report
  • Pages:65

MarketVIEW: Chlamydia trachomatis vaccines Global market forecast

Chlamydia trachomatis (CT) is an intracellular Gram-negative bacterium and a leading cause worldwide of sexually-transmitted disease and preventable blindness. The pathogen is a major cause of serious reproductive complications in the female with outcomes such as pelvic inflammatory disease (PID) and ectopic pregnancies.

Although diagnosed infections with Chlamydia trachomatis are curable with antibiotic therapy the vast majority infections are "silent" and unrecognized. This is of concern due to continued transmission especially among individuals below 30 years of age. Prophylatic vaccines could prevent CT primary infection, reinfection or lessen the incidence and severity of PID, or similar long-term sequelae. A key question for vaccine manufacturers is whether a CT vaccine would be deployed alongside HPV vaccines in the preadolescent population, thus providing a sizeable commercial opportunity.

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for a putative CT vaccine until 2035. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on new adolescent vaccines.

  • Contents - Summary presentation (MS PowerPoint based)
    • Executive Summary
    • Commercial model - key outputs
    • Total available demand: Chlamydia vaccine, global, (000s doses)
    • Total available demand: Chlamydia vaccine, high-income markets, (000s doses)
    • Total available demand: Chlamydia vaccine, emerging markets, (000s doses)
    • Total available market: Chlamydia vaccine, global, ($ 000s)
    • Total available market: Chlamydia vaccine, by market, ($ 000s)
    • Total available market: Chlamydia vaccine, price sensitivity analysis, ($ 000s)
    • Chlamydia vaccine: country volume analysis, 2025 (000s doses)
    • Chlamydia vaccine: country value analysis, 2025 ($ 000s)
    • The role of a CT vaccine
    • Commercial model - key assumptions
    • Pricing
    • Model forecast comparisons: June 2011 v current
    • Chlamydia vaccine opportunity: target product profile
    • Overall commercial model assumptions per country
    • Chlamydia trachomatis: brief background
    • Clinical features
    • Chlamydia trachomatis: natural history of infection
    • Chlamydia trachomatis: global incidence
    • Chlamydia trachomatis: global prevalence
    • US epidemiology
    • UK epidemiology
    • Reasons for increasing incidence
    • Potential impact of a CT vaccine
    • Competitor landscape: overview
    • Competitive environment: major players
    • Chlamydia trachomatis vaccine - HPV, a relevant case study?
    • HPV vaccines: analysis of country uptake
    • Bibliography
    • Disclaimer
    • About VacZine Analytics
  • PAGES: 57 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
  • Contents - Vaccine demand model (MS Excel-based)
    • Title Sheet
    • Scenario definition
    • Value Scenario Analysis
    • Value Summary (Western)
    • Volume Summary (Western)
    • Value Summary (Emerging)
    • Volume Summary (Emerging)
    • Charts - volume (Western)
    • Charts - value (Western)
    • Charts - value/volume (Western)
    • Females (Western) ?
    • US (13 yrs/ 14 - 18 yrs)
    • Canada
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Other EU
    • Australia
    • Japan
    • Females (Emerging) ?
    • Brazil
    • Russia
    • India
    • China
    • Mexico
    • Population database
    • Competition - IP landscape
    • Assumptions - major markets
    • Back page
    • About VacZine Analytics
    • Disclaimer
    • WORKSHEETS: 65
    • BUY THIS REPORT
    • ASK INFO SPECIALIST 24/7
    • Alison - online now
    • 00 44 208 816 85 81
    • Send Message @Alison
    • Share
+44 20 8816 8548

Ask a question about MarketVIEW: Chlamydia trachomatis vaccines

Enter the characters you see in the picture below
Captcha